These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 31493514)

  • 21. Use of Flecainide for the Treatment of Atrial Fibrillation.
    Echt DS; Ruskin JN
    Am J Cardiol; 2020 Apr; 125(7):1123-1133. PubMed ID: 32044037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomised double blind trial of oral versus intravenous flecainide for the cardioversion of acute atrial fibrillation.
    Alp NJ; Bell JA; Shahi M
    Heart; 2000 Jul; 84(1):37-40. PubMed ID: 10862585
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safe and efficacious dosage of flecainide acetate for treating equine atrial fibrillation.
    Ohmura H; Nukada T; Mizuno Y; Yamaya Y; Nakayama T; Amada A
    J Vet Med Sci; 2000 Jul; 62(7):711-5. PubMed ID: 10945288
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral antiarrhythmic drugs in converting recent onset atrial fibrillation.
    Deneer VH; Borgh MB; Kingma JH; Lie-A-Huen L; Brouwers JR
    Pharm World Sci; 2004 Apr; 26(2):66-78. PubMed ID: 15085940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pilot study: Noninvasive monitoring of oral flecainide's effects on atrial electrophysiology during persistent human atrial fibrillation using the surface electrocardiogram.
    Husser D; Binias KH; Stridh M; Sornmo L; Olsson SB; Molling J; Geller C; Klein HU; Bollmann A
    Ann Noninvasive Electrocardiol; 2005 Apr; 10(2):206-10. PubMed ID: 15842433
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Flecainide and encainide.
    Furlanello F; Vergara G; Bettini R; Mosna G; Gramegna L; Disertori M
    Eur Heart J; 1987 Mar; 8 Suppl A():33-40. PubMed ID: 3107989
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-arrhythmic effects of I (Na), I (Kr), and combined I (Kr)-I (CaL) blockade in an experimental model of acute stretch-related atrial fibrillation.
    Kalifa J; Bernard M; Gout B; Bril A; Cozma D; Laurent P; Chalvidan T; Deharo JC; Djiane P; Cozzone P; Maixent JM
    Cardiovasc Drugs Ther; 2007 Feb; 21(1):47-53. PubMed ID: 17356910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacologic cardioversion of chronic atrial fibrillation in the goat by class IA, IC, and III drugs: a comparison between hydroquinidine, cibenzoline, flecainide, and d-sotalol.
    Wijffels MC; Dorland R; Allessie MA
    J Cardiovasc Electrophysiol; 1999 Feb; 10(2):178-93. PubMed ID: 10090222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
    Naccarelli GV; Wolbrette DL; Khan M; Bhatta L; Hynes J; Samii S; Luck J
    Am J Cardiol; 2003 Mar; 91(6A):15D-26D. PubMed ID: 12670638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Flecainide How and When: A Practical Guide in Supraventricular Arrhythmias.
    Lavalle C; Magnocavallo M; Straito M; Santini L; Forleo GB; Grimaldi M; Badagliacca R; Lanata L; Ricci RP
    J Clin Med; 2021 Apr; 10(7):. PubMed ID: 33918105
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravenous flecainide acetate for the clinical management of paroxysmal tachycardias.
    Nathan AW; Camm AJ; Bexton RS; Hellestrand KJ
    Clin Cardiol; 1987 May; 10(5):317-22. PubMed ID: 3109795
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Favorable effects of flecainide in transvenous internal cardioversion of atrial fibrillation.
    Boriani G; Biffi M; Capucci A; Bronzetti G; Ayers GM; Zannoli R; Branzi A; Magnani B
    J Am Coll Cardiol; 1999 Feb; 33(2):333-41. PubMed ID: 9973012
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Flecainide toxicity in a neonate with supraventricular tachycardia.
    Zeigler VL; Peterson J
    Heart Lung; 1991 Nov; 20(6):689-91. PubMed ID: 1960074
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Arrhythmias in the intensive care patient.
    Trappe HJ; Brandts B; Weismueller P
    Curr Opin Crit Care; 2003 Oct; 9(5):345-55. PubMed ID: 14508146
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of intravenous flecainide in horses with naturally-occurring atrial fibrillation.
    van Loon G; Blissitt KJ; Keen JA; Young LE
    Equine Vet J; 2004 Nov; 36(7):609-14. PubMed ID: 15581326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tissue velocity imaging of the left atrium predicts response to flecainide in patients with acute atrial fibrillation.
    Limantoro I; De Vos CB; Delhaas T; Marcos E; Blaauw Y; Weijs B; Tieleman RG; Pisters R; Schotten U; Van Gelder IC; Crijns HJ
    Heart Rhythm; 2014 Mar; 11(3):478-84. PubMed ID: 24321238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of flecainide acetate in rapid atrial fibrillation complicating Wolff-Parkinson-White syndrome.
    Kappenberger LJ; Fromer MA; Shenasa M; Gloor HO
    Clin Cardiol; 1985 Jun; 8(6):321-6. PubMed ID: 4006340
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pharmacology of modern anti-arrhythmia drugs in therapy of supraventricular tachycardia].
    Honerjäger P; Schmidt G
    Z Gesamte Inn Med; 1993 Sep; 48(9):425-9. PubMed ID: 8212747
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Too little, too late: chasing atrial fibrillation with sodium channel antagonists.
    Anderson ME
    J Cardiovasc Electrophysiol; 2006 Jun; 17(6):655-6. PubMed ID: 16836717
    [No Abstract]   [Full Text] [Related]  

  • 40. Flecainide in the Wolff-Parkinson-White syndrome.
    Crozier I
    Am J Cardiol; 1992 Aug; 70(5):26A-32A. PubMed ID: 1509995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.